Tempus AI (TEM) announced an expanded, multi-year collaboration with Gilead Sciences (GILD) aimed at building and advancing Gilead’s oncology pipeline. To date, Gilead has leveraged Tempus’ extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy, health outcomes analysis and clinical real world evidence. The expanded agreement provides Gilead with enterprise-wide access to Tempus’ AI-driven Lens platform, unlocking access to broader datasets across multiple indications and integrating dedicated Tempus analytical services.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade TEMPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Largest borrow rate increases among liquid names
- Tempus AI announces results from ALERT trial, study met primary endpoint
- Tempus AI price target lowered to $60 from $95 at Guggenheim
- Cathie Wood Rotates $84M Out of Meta, Nvidia, Chip Stocks – Here’s Why
- Cathie Wood’s ARK Investment buys 61K shares of Tempus AI today